Related Experiment Video

Updated: Jun 28, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets

Bora Gurel1, Tsuyoshi Iwata, Cheryl M Koh

  • 1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Advances in Anatomic Pathology
|October 25, 2008
PubMed

Insights

Recent molecular studies reveal new insights into prostate cancer development and progression. These findings are paving the way for improved diagnostic and prognostic tools in clinical practice.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer is a leading cause of cancer death in American men.
  • The postgenomic era has accelerated the identification of genetic alterations in prostate cancer.
  • Understanding molecular pathogenesis is crucial for developing new diagnostic and therapeutic strategies.

Purpose of the Study:

  • To update surgical pathologists and residents on recent molecular findings in prostate cancer.
  • To highlight somatic molecular alterations in prostate cancer development and progression.
  • To discuss the clinical application of new molecular diagnostic approaches.

Main Methods:

  • Review of recent scientific literature on prostate cancer molecular pathobiology.
  • Focus on somatic genome alterations and germline heritable risk factors.
  • Analysis of studies translating molecular discoveries into clinical practice.

Main Results:

  • Significant increase in identified somatic and germline alterations in prostate cancer.
  • Emerging understanding of prostate cancer pathogenesis.
  • Early clinical translation of molecular findings for diagnosis and prognosis.

Conclusions:

  • Molecular research is rapidly advancing the understanding of prostate cancer.
  • New molecular targets are being identified for diagnosis, prognosis, and treatment prediction.
  • Clinical application of molecular diagnostics in prostate cancer is evolving.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...